. 2021 Apr 17;34(6):2017–2026. doi: 10.1007/s40620-021-01040-y

Table 3.

Biopsy findings on rejection in transplant recipients after detection of de novo donor- specific antibodies (DSA)

Kind of rejection	All biopsies n = 84	Patients with eGFR loss ≥ 10 ml/a and/or proteinuria > 300 mg/g creatinine n = 50	Patients with eGFR loss < 10 ml/a and proteinuria < 300 mg/g creatinine n = 34	p
Borderline n, (%)	9 (10.7%)	4 (8.0%)	5 (14.7%)	0.329
ABMR n, (%) - acute - chronic - combined	40 (47.6%) 26 (65.0%) 6 (15.0%) 8 (20.0%)	25 (50.0%) 15 (60.0%) 3 (12.0%) 7 (28.0%)	15 (44.1%) 11 (73.3%) 3 (20.0%) 1 (6.7%)	0.596 0.237 0.602 0.066
Cellular n, (%) - Banff 1a - Banff 1b - Banff 2	11 (13.1%) 6 (54.55%) 3 (27.27%) 2 (18.18%)	6 (17.7%) 5 (83.3%) 1 (16.7%) 0 (0.0%)	5 (14.7%) 1 (20.0%) 2 (40.0%) 2 (40.0%)	0.718 0.066 0.201 0.039
Combined cellular and ABMR	17 (20.2%)	13 (38.2%)	4 (11.8%)	0.111
No rejection n, (%)	7 (8.3%)	2 (4.0%)	5 (14.7%)	0.175

Kind of rejection

All biopsies
n = 84

Patients with eGFR loss ≥ 10 ml/a and/or proteinuria > 300 mg/g creatinine
n = 50

Patients with eGFR loss < 10 ml/a and proteinuria < 300 mg/g creatinine
n = 34

Borderline

n, (%)

(10.7%)

(8.0%)

(14.7%)

0.329

ABMR

n, (%)

- acute

- chronic

- combined

(47.6%)

26 (65.0%)

6 (15.0%)

8 (20.0%)

(50.0%)

15 (60.0%)

3 (12.0%)

7 (28.0%)

(44.1%)

11 (73.3%)

3 (20.0%)

1 (6.7%)

0.596

0.237

0.602

0.066

Cellular

n, (%)

- Banff 1a

- Banff 1b

- Banff 2

(13.1%)

6 (54.55%)

3 (27.27%)

2 (18.18%)

(17.7%)

5 (83.3%)

1 (16.7%)

0 (0.0%)

(14.7%)

1 (20.0%)

2 (40.0%)

0.718

0.066

0.201

0.039

Combined

cellular and

ABMR

(20.2%)

(38.2%)

(11.8%)

0.111

No rejection

n, (%)

(8.3%)

(4.0%)

(14.7%)

0.175

ABMR antibody-mediated rejection